MedDataX Logo

REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients

NCT ID: NCT02001545

Last Updated: 2014-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

814 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-02-28

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RE-ACT is a national, multi-centre, observational, prospective, longitudinal cohort study which will include patients hospitalized for ACS within 24 hours of symptom onset and who have a final diagnosis of ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI). This study aims to describe the short-term (at the end of the first month after index event) antithrombotic management patterns in a "real-life" setting for patients hospitalized with an acute coronary syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with STEMI and NSTEMI

Patients aged 18 years or older, hospitalized and diagnosed with STEMI (ST-segment elevation myocardial infarction) or NSTEMI (non-ST-segment elevation myocardial infarction) within 24 hours of symptom onset.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provision of subject informed consent
* Patients hospitalized and diagnosed with STEMI or NSTEMI
* Hospitalized within 24 hours of onset of symptoms or transferred from another hospital within 24 hours of the onset of symptoms

Exclusion Criteria

* STEMI and NSTEMI precipitated by or as a complication of surgery, trauma, or GI bleeding or post-PCI.
* STEMI and NSTEMI occurring in patients already hospitalized for other reasons.
* Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the complete follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elina Trendafilova, Ass. Prof. M.D

Role: PRINCIPAL_INVESTIGATOR

National Cardiology Hospital, Sofia

Vasil Velchev, Ass. Prof. M.D.

Role: PRINCIPAL_INVESTIGATOR

University Hospital St. Anna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Blagoevgrad, , Bulgaria

Site Status

Research Site

Burgas, , Bulgaria

Site Status

Research Site

Lovech, , Bulgaria

Site Status

Research Site

Plovdiv, , Bulgaria

Site Status

Research Site

Rousse, , Bulgaria

Site Status

Research Site

Sofia, , Bulgaria

Site Status

Research Site

Varna, , Bulgaria

Site Status

Research Site

Vratsa, , Bulgaria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bulgaria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CBG-XXX-2013/1

Identifier Type: -

Identifier Source: org_study_id